Payment overview · 2025
General Payments
$3,506.42
98 reported records · 15 companies
Healthcare provider profile · identity verified
Aaron W Hayson, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · TALLAHASSEE, FL · NPI 1629463195
Verified facts
What the public records show
CMS Open Payments records show Aaron W Hayson, MD received $3,506.42 in general payments during 2025 across 98 reported records.
Philips North America LLC accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $892.79 | 25.5% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $786.76 | 22.4% | 35 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $510.12 | 14.6% | 17 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $348.87 | 9.9% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $321.53 | 9.2% | 15 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $193.24 | 5.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$166.10 | 4.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $79.38 | 2.3% | 2 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $55.31 | 1.6% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $35.32 | 1.0% | 4 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $28.91 | 0.8% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $26.91 | 0.8% | 1 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $22.44 | 0.6% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $21.28 | 0.6% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,799.01 | 96 |
| Travel and Lodging | $707.41 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Azurion 7 B20 Normalized: azurion 7 b20 |
Device | Philips North America LLC | $758.65 | 5 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $482.46 | 15 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $348.87 | 9 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $193.24 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $166.10 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $165.18 | 12 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $165.18 | 12 | 2025 |
Source payment records
|
|||||
| Azurion 7 M20 Normalized: azurion 7 m20 |
Device | Philips North America LLC | $134.14 | 2 | 2025 |
Source payment records
|
|||||
| General - Angioplasty Normalized: general angioplasty |
Device | Boston Scientific Corporation | $128.85 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $112.21 | 3 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $106.81 | 7 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $96.40 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $79.38 | 2 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $73.94 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $58.68 | 3 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $55.41 | 3 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $55.31 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $47.16 | 1 | 2025 |
Source payment records
|
|||||
| Epic Vascular Normalized: epic vascular |
Device | Boston Scientific Corporation | $46.91 | 2 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| Express LD Iliac / Biliary Normalized: express ld iliac biliary |
Device | Boston Scientific Corporation | $41.55 | 3 | 2025 |
Source payment records
|
|||||
| Innova Vascular Normalized: innova vascular |
Device | Boston Scientific Corporation | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $35.20 | 3 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $27.66 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| General - Angiography Normalized: general angiography |
Device | Boston Scientific Corporation | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| General - Guidewires Normalized: general guidewires |
Device | Boston Scientific Corporation | $20.18 | 2 | 2025 |
Source payment records
|
|||||
| General - Metallic Stents Normalized: general metallic stents |
Device | Boston Scientific Corporation | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $11.54 | 1 | 2025 |
Source payment records
|
|||||
| 2cm Peripheral Cutting Balloon Normalized: 2cm peripheral cutting balloon |
Device | Boston Scientific Corporation | $6.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 19 |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,506.42 · 98 records | Philips North America LLC | 2cm Peripheral Cutting Balloon, APLIGRAF, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AngioJet Ultra 5000A, Azurion 7 B20, Azurion 7 M20, CGuard Prime Carotid Stent System, CLOTTRIEVER BOLD CATHETER, COOK, CT THROMBECTOMY SYSTEM KIT, ELUVIA, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, EkoSonic, Epic Vascular, Express LD Iliac / Biliary, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GRAFIX PL, General - Angiography, General - Angioplasty, General - Guidewires, General - Metallic Stents, General - Thrombectomy, General - Vascular Intervention, IMPEDE EMBOLIZATION PLUG, Indigo System, Innova Vascular, JETSTREAM SC, OASIS, OptiCross 35, RUBY Coil, Ranger, STRAVIX, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TEG6S HEMOSTASIS SYSTEM | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error